跳至主要内容
临床试验/ITMCTR2026001746
ITMCTR2026001746进行中(未招募)Unknown

Shuganhuazhuo Formula in the Combined Treatment of Advanced Liver Cancer with Damp-Heat and Blood Stasis: A Prospective Clinical Study

Zhejiang Cancer Hospital0 个研究点开始时间: 2026年9月9日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • According to the National Health Commission's "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026)", clinically or pathologically diagnosed as primary liver cancer;
  • Barcelona Clinic Liver Cancer (BCLC) stage is C;
  • Planning to receive second-line or third-line anti-tumor therapies;
  • The dominant syndrome in TCM diagnosis is dampness or heat;
  • Age: = 18 years and = 75 years.

排除标准

  • Expected survival is less than 3 months;
  • Patients with pathological types of intrahepatic cholangiocarcinoma or mixed cell carcinoma;
  • Comorbid severe heart, liver, kidney, and other vital organ dysfunction: heart (NYHA functional class II), liver (AST and/or ALT > 3 times normal, or bilirubin > 3 times normal), kidney (creatinine clearance (CrCl, Cockcroft–Gault) < 60 mL/min);
  • Concurrent with other malignant tumors.

研究者

相似试验